Assessing the efficacy and safety in novel drug candidates for Alzheimer's disease requires a rigorous evaluation system. Preclinical studies typically involve in vitro and in vivo assays to assess its potential ability in targeting disease-related pathways. Once promising candidates emerge, they undergo clinical trials that are conducted on human